OCUL SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

News

TYPE

HEADLINE

FILED AT

8-K

NEWOcular Therapeutix Announces Board of Directors Changes and New Director Compensation

Nov 9, 2026

8-K

NEWOcular Therapeutix Reports Q3 2026 Financial Results and Provides AXPAXLI™ Development and Regulatory Updates

Nov 9, 2026

8-K

Ocular Therapeutix Announces Resignation of Chief Strategy Officer Sanjay Nayak

Oct 16, 2026

8-K

Ocular Therapeutix Reports Q2 2026 Financial Results and Progress Toward AXPAXLI NDA Submission

Aug 3, 2026

8-K

Ocular Therapeutix, Inc. Announces Executive Appointment and 2026 Annual Meeting Results

Jun 12, 2026

8-K

Ocular Therapeutix Reports Q1 2026 Financial Results and Progress on AXPAXLI Clinical Programs

May 5, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Sep 30, 2025

424B5

30,800,000 Shares

Dec 14, 2023

424B5

Common Stock

Dec 13, 2023

424B5

Up to $100,000,000 Common Stock-

Aug 9, 2021

424B5

3,725,000 Shares-

Dec 16, 2020

424B5

Gain on Disposition of Common Stock-

Dec 14, 2020

Registrations

TYPE

HEADLINE

FILED AT

S-8

NEWForm S-8 - Securities to be offered to employees in employee benefit plans

Nov 9, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 3, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 5, 2026

S-3ASR

SHARE RESALE REGISTRATION |

Sep 30, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jun 11, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Nov 14, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 30, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 30, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 18, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 7, 2024

Ownerships

TYPE

HEADLINE

FILED AT

NEWSaroj Namrata (Reporting)

Nov 9, 2026

144

Form 144 - Report of proposed sale of securities

Nov 5, 2026

Anderman Todd (Reporting)

Oct 13, 2026

144

Form 144 - Report of proposed sale of securities

Oct 8, 2026

Kaiser Peter (Reporting)

Oct 6, 2026

Heier Jeffrey S. (Reporting)

Oct 6, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Nov 17, 2023

CORRESP

Form CORRESP - Correspondence

Nov 14, 2023

LETTER

Form UPLOAD - SEC-generated letter

Nov 13, 2023

EFFECT

Form EFFECT - Notice of Effectiveness

May 11, 2022

CT ORDER

Form CT ORDER - Confidential treatment order

Oct 24, 2019

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 30, 2019

Ocular Therapeutix, Inc. OCUL · SEC Filings